|
SHENZHEN, China, Feb. 10, 2026 /PRNewswire/ -- Shenzhen Topband Co., Ltd. (Stock Code: 002139.SZ) marks its 30th anniversary, reflecting three decades of evolution that mirrors the broader transformation of Chinese manufacturing — from domestic capability-building to global innovation partnership and sustainable operations.
From Local Innovation to Global Integration
Founded in the 1990s, Topband independently developed core controller technologies, beginning with air-conditioning controllers and expanding across appliance categories to earn international recognition.
This foundation enabled Topband to develop its integrated "Four Electrics and One Network" technology platform — encompassing control systems, motors, batteries, power supplies, and IoT connectivity. As the global intelligent control market evolved and customer requirements became more complex, this integrated capability positioned Topband to expand beyond home appliances into power tools, industrial controls, digital energy systems, and robotics. Today, the company serves leading brands worldwide, including first-tier global power tool companies and multiple Top 100 home appliance brands, reflecting its evolution from specialized component supplier to comprehensive solutions partner.
Operational Excellence Supporting Customer Success
Through implementation of ISC (Integrated Supply Chain) and IPD (Integrated Product Development) frameworks, Topband built a customer-centric organization designed for efficient collaboration from initial concept through mass production. This integrated operational system enables true end-to-end solutions — from R&D and engineering through manufacturing and delivery — allowing customers to consolidate supplier relationships, reduce development complexity, and accelerate time-to-market.
To date, Topband has delivered 1.8 billion intelligent solutions globally. Since its 2007 IPO, the company has achieved over 20-fold revenue growth, demonstrating operational resilience and the ability to scale capabilities in response to market demands.
Localized Manufacturing for Global Markets
Topband's technology capabilities are supported by a diversified global manufacturing network designed to meet evolving supply chain requirements. While facilities in China provide established, cost-effective production, operations in India, Vietnam, Romania, and Mexico offer localized supply with consistent quality and responsiveness across Asia, Europe, and the Americas.
"Our goal extends beyond global manufacturing to creating genuine value in each market we serve," said Mr. Wu, Chairman and CEO. "This means delivering not just products, but responsive partnership — providing rapid, localized delivery and flexible support that adapts to regional needs and launch timelines."
By 2025, Topband's production outside China is projected to exceed 20% of total output, reflecting the company's strategic commitment to distributed manufacturing. Currently, international clients represent 70% of the customer base, underscoring deep integration into global supply networks.
Sustainable Operations as a Long-Term Commitment
Since 2022, Topband's Chinese facilities have deployed on-site photovoltaic solar systems generating clean energy for production operations. In 2024, the company earned EcoVadis Gold certification, placing it in the top 5% of assessed enterprises globally — validating sustainability performance across environmental impact, labor practices, ethics, and sustainable procurement.
Beyond environmental stewardship, Topband maintains substantial investment in innovation. The company's R&D team of about 2,000 professionals is supported by consistent annual investment of approximately 8% of revenue — a commitment maintained even during market volatility.
Positioned for the Next Chapter
"From a team of 20 to nearly 10,000 employees worldwide, Topband's 30-year journey reflects the evolution of Chinese manufacturing itself — from learning and adaptation to innovation and global partnership," said Mr. Wu, Chairman and CEO. "Looking forward, we remain committed to delivering quality, sustainability, and responsive collaboration that creates lasting value for customers and stakeholders worldwide."
As artificial intelligence reshapes manufacturing, Topband is actively expanding into AI energy infrastructure, embodied intelligence, industrial automation, and smart hardware — translating advanced technology into practical solutions.
About Topband
Topband (Stock Code: 002139.SZ) is a global provider of intelligent control solutions and integrated components, serving leading brands in home appliances, power tools, industrial controls, digital energy, and robotics. With R&D and manufacturing facilities across China, India, Vietnam, Romania, and Mexico, Topband delivers localized, sustainable solutions to customers worldwide. For more information, visit https://www.topband.com/en.
SHENZHEN, China, Feb. 10, 2026 /PRNewswire/ -- Shenzhen Topband Co., Ltd. (Stock Code: 002139.SZ) marks its 30th anniversary, reflecting three decades of evolution that mirrors the broader transformation of Chinese manufacturing — from domestic capability-building to global innovation partnership and sustainable operations.
From Local Innovation to Global Integration
Founded in the 1990s, Topband independently developed core controller technologies, beginning with air-conditioning controllers and expanding across appliance categories to earn international recognition.
This foundation enabled Topband to develop its integrated "Four Electrics and One Network" technology platform — encompassing control systems, motors, batteries, power supplies, and IoT connectivity. As the global intelligent control market evolved and customer requirements became more complex, this integrated capability positioned Topband to expand beyond home appliances into power tools, industrial controls, digital energy systems, and robotics. Today, the company serves leading brands worldwide, including first-tier global power tool companies and multiple Top 100 home appliance brands, reflecting its evolution from specialized component supplier to comprehensive solutions partner.
Operational Excellence Supporting Customer Success
Through implementation of ISC (Integrated Supply Chain) and IPD (Integrated Product Development) frameworks, Topband built a customer-centric organization designed for efficient collaboration from initial concept through mass production. This integrated operational system enables true end-to-end solutions — from R&D and engineering through manufacturing and delivery — allowing customers to consolidate supplier relationships, reduce development complexity, and accelerate time-to-market.
To date, Topband has delivered 1.8 billion intelligent solutions globally. Since its 2007 IPO, the company has achieved over 20-fold revenue growth, demonstrating operational resilience and the ability to scale capabilities in response to market demands.
Localized Manufacturing for Global Markets
Topband's technology capabilities are supported by a diversified global manufacturing network designed to meet evolving supply chain requirements. While facilities in China provide established, cost-effective production, operations in India, Vietnam, Romania, and Mexico offer localized supply with consistent quality and responsiveness across Asia, Europe, and the Americas.
"Our goal extends beyond global manufacturing to creating genuine value in each market we serve," said Mr. Wu, Chairman and CEO. "This means delivering not just products, but responsive partnership — providing rapid, localized delivery and flexible support that adapts to regional needs and launch timelines."
By 2025, Topband's production outside China is projected to exceed 20% of total output, reflecting the company's strategic commitment to distributed manufacturing. Currently, international clients represent 70% of the customer base, underscoring deep integration into global supply networks.
Sustainable Operations as a Long-Term Commitment
Since 2022, Topband's Chinese facilities have deployed on-site photovoltaic solar systems generating clean energy for production operations. In 2024, the company earned EcoVadis Gold certification, placing it in the top 5% of assessed enterprises globally — validating sustainability performance across environmental impact, labor practices, ethics, and sustainable procurement.
Beyond environmental stewardship, Topband maintains substantial investment in innovation. The company's R&D team of about 2,000 professionals is supported by consistent annual investment of approximately 8% of revenue — a commitment maintained even during market volatility.
Positioned for the Next Chapter
"From a team of 20 to nearly 10,000 employees worldwide, Topband's 30-year journey reflects the evolution of Chinese manufacturing itself — from learning and adaptation to innovation and global partnership," said Mr. Wu, Chairman and CEO. "Looking forward, we remain committed to delivering quality, sustainability, and responsive collaboration that creates lasting value for customers and stakeholders worldwide."
As artificial intelligence reshapes manufacturing, Topband is actively expanding into AI energy infrastructure, embodied intelligence, industrial automation, and smart hardware — translating advanced technology into practical solutions.
About Topband
Topband (Stock Code: 002139.SZ) is a global provider of intelligent control solutions and integrated components, serving leading brands in home appliances, power tools, industrial controls, digital energy, and robotics. With R&D and manufacturing facilities across China, India, Vietnam, Romania, and Mexico, Topband delivers localized, sustainable solutions to customers worldwide. For more information, visit https://www.topband.com/en.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Topband Marks 30 Years: From Local Controller Manufacturer to Global Intelligent Solutions Partner
|
ROME, Feb. 10, 2026 /PRNewswire/ -- IRBM, a leader in early drug discovery research, has announced a major scientific breakthrough with the discovery of a novel and potent allosteric inhibitor targeting the Zika virus (ZIKV) protease (NS2B-NS3). The findings, published in Nature Communications (doi: 10.1038/s41467-026-68943-x), demonstrate the molecule's efficacy in preclinical models and represent a promising new approach to combat ZIKV infections.
Mosquito-borne ZIKV poses a serious public health threat due to its association with severe neurological complications. With no approved antivirals or vaccines currently available, there is an urgent need for new treatment options.
IRBM scientists identified a small molecule that binds to a previously uncharacterized allosteric site on the NS2B-NS3 protease, a key enzyme required for viral replication. The inhibitor effectively suppressed protease activity in biochemical and cellular assays and demonstrated significant antiviral activity in animal models. It also exhibited a favorable safety and pharmacokinetic profile, supporting its potential for clinical development. Notably, this mechanism may extend to other flaviviruses including dengue, yellow fever, and West Nile, suggesting broader therapeutic potential.
IRBM's integrated approach, combining high-content phenotypic screening, computational modeling, mechanistic enzymology, iterative medicinal chemistry, and ADME profiling allowed the team to rapidly advance from initial hit identification to preclinical candidate selection.
"This discovery marks an important milestone in antiviral drug development," said Carlo Toniatti, MD, PhD, Chief Scientific Officer at IRBM. "By leveraging cutting-edge medicinal chemistry and integrated screening technologies, our team has delivered a novel ZIKV protease inhibitor with compelling preclinical activity."
The achievement, funded by the Region of Lazio, is the result of a collaborative initiative originating from CNCCS, and it opens a promising path toward targeted antiviral therapies that could fill a critical gap in global public health preparedness. It also reinforces the joint commitment of CNCCS and IRBM to tackle rare and neglected diseases with innovative science.
"Innovation in drug discovery never happens alone. At IRBM, we aim to act as a bridge between academic discoveries and the clinic, and the success of this project demonstrates the impact that effective public–private partnerships can have on advancing new therapies," added Matteo Liguori, CEO and Founder of IRBM.
About IRBM IRBM is a leading research organization specializing in early drug discovery. With decades of expertise and a proven track record of delivering innovative preclinical candidates, IRBM is known for its rigorous, multidisciplinary approach to designing and executing complex experiments for the toughest drug discovery challenges. IRBM advances programs across a wide spectrum of modalities and therapeutic areas, including antivirals, oncology, neuroscience, rare diseases, and beyond.
About CNCCS CNCCS is a public-private consortium between IRBM, CNR, ISS, and the University of La Sapienza, which acts as a lead factory for drug discovery programs, integrating a chemical compound repository with a high-throughput screening (HTS) platform. Its mission is to act as a bridge between academic research and pharmaceutical development, with a particular focus on targeting rare, neglected, and poverty-related diseases.
Website: www.irbm.com
ROME, Feb. 10, 2026 /PRNewswire/ -- IRBM, a leader in early drug discovery research, has announced a major scientific breakthrough with the discovery of a novel and potent allosteric inhibitor targeting the Zika virus (ZIKV) protease (NS2B-NS3). The findings, published in Nature Communications (doi: 10.1038/s41467-026-68943-x), demonstrate the molecule's efficacy in preclinical models and represent a promising new approach to combat ZIKV infections.
Mosquito-borne ZIKV poses a serious public health threat due to its association with severe neurological complications. With no approved antivirals or vaccines currently available, there is an urgent need for new treatment options.
IRBM scientists identified a small molecule that binds to a previously uncharacterized allosteric site on the NS2B-NS3 protease, a key enzyme required for viral replication. The inhibitor effectively suppressed protease activity in biochemical and cellular assays and demonstrated significant antiviral activity in animal models. It also exhibited a favorable safety and pharmacokinetic profile, supporting its potential for clinical development. Notably, this mechanism may extend to other flaviviruses including dengue, yellow fever, and West Nile, suggesting broader therapeutic potential.
IRBM's integrated approach, combining high-content phenotypic screening, computational modeling, mechanistic enzymology, iterative medicinal chemistry, and ADME profiling allowed the team to rapidly advance from initial hit identification to preclinical candidate selection.
"This discovery marks an important milestone in antiviral drug development," said Carlo Toniatti, MD, PhD, Chief Scientific Officer at IRBM. "By leveraging cutting-edge medicinal chemistry and integrated screening technologies, our team has delivered a novel ZIKV protease inhibitor with compelling preclinical activity."
The achievement, funded by the Region of Lazio, is the result of a collaborative initiative originating from CNCCS, and it opens a promising path toward targeted antiviral therapies that could fill a critical gap in global public health preparedness. It also reinforces the joint commitment of CNCCS and IRBM to tackle rare and neglected diseases with innovative science.
"Innovation in drug discovery never happens alone. At IRBM, we aim to act as a bridge between academic discoveries and the clinic, and the success of this project demonstrates the impact that effective public–private partnerships can have on advancing new therapies," added Matteo Liguori, CEO and Founder of IRBM.
About IRBM IRBM is a leading research organization specializing in early drug discovery. With decades of expertise and a proven track record of delivering innovative preclinical candidates, IRBM is known for its rigorous, multidisciplinary approach to designing and executing complex experiments for the toughest drug discovery challenges. IRBM advances programs across a wide spectrum of modalities and therapeutic areas, including antivirals, oncology, neuroscience, rare diseases, and beyond.
About CNCCS CNCCS is a public-private consortium between IRBM, CNR, ISS, and the University of La Sapienza, which acts as a lead factory for drug discovery programs, integrating a chemical compound repository with a high-throughput screening (HTS) platform. Its mission is to act as a bridge between academic research and pharmaceutical development, with a particular focus on targeting rare, neglected, and poverty-related diseases.
Website: www.irbm.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
IRBM Reports Breakthrough in Zika Virus Drug Discovery
